LALPATHLABDr. Lal PathLabs Ltd
Dr. Lal PathLabs invests up to ₹30.3 crore in a subsidiary to fund the purchase of the rest of Centrapath Labs
- Mergers & acquisitions
- Healthcare
Dr. Lal PathLabs Limited has told the exchanges that on 12 Oct 2026 it made a further investment in its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL), by subscribing to PUPL’s equity shares for cash. The amount is stated as not exceeding ₹30.3 crore.
The filing says the money is meant to fund PUPL’s purchase of the remaining 30% equity stake in CentraPath Labs Private Limited, a subsidiary of PUPL. After that purchase, CentraPath will become a wholly owned subsidiary of PUPL. The company describes the subscription as a related party transaction, because PUPL is its subsidiary, done on an arm’s length basis, and says PUPL will remain a wholly owned subsidiary. The investment is complete, and no government or regulatory approval was needed.
PUPL’s turnover is given as ₹7.23 crore for FY2026, ₹7.10 crore for FY2025 and ₹7.28 crore for FY2024.
Inference
This filing records the funding step, on 12 Oct 2026, ahead of the purchase of the remaining stake in CentraPath. The company’s separate filing on 13 Oct 2026 covers the stake purchase itself.
The money moves within the group, from the listed company to its subsidiary, so the group’s ownership of CentraPath rises from 70% to 100% once the purchase is done.
Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
